Vyne Therapeutics (VYNE) shares were down more than 71% in early Wednesday trading after the company said its phase 2b trial evaluating repibresib gel in nonsegmental vitiligo did not meet its primary endpoint.
The trial also missed a key secondary endpoint and based on the data, Vyne Therapeutics said it will terminate the trial.
Vyne Therapeutics said it plans to seek a development and commercialization partner for repibresib.
Price: 0.41, Change: -1.03, Percent Change: -71.74
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.